Compare ARQQ & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQQ | CERS |
|---|---|---|
| Founded | 2017 | 1991 |
| Country | United Kingdom | United States |
| Employees | 91 | N/A |
| Industry | Computer Software: Prepackaged Software | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.9M | 276.0M |
| IPO Year | N/A | 1996 |
| Metric | ARQQ | CERS |
|---|---|---|
| Price | $14.51 | $1.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | 344.4K | ★ 1.0M |
| Earning Date | 05-21-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | $381.13 | $19.95 |
| Revenue Next Year | $212.00 | $8.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $11.52 | $1.15 |
| 52 Week High | $62.00 | $2.96 |
| Indicator | ARQQ | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 49.76 | 52.85 |
| Support Level | $11.72 | $1.93 |
| Resistance Level | $17.75 | $2.15 |
| Average True Range (ATR) | 1.20 | 0.10 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 45.72 | 47.54 |
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.